(99m) 1. Pre-Clinical Testing of Acizol: an Efficacy in Experimental Cardiology

Acizol, an antidote to carbon oxide that belongs to a series of zinc organic compounds, is an effective antioxidant. We studied Acizol's specific pharmacological activity at intragastric introduction on cardiac ischemia. Two experimental models were used (cardiac infarction and calcium arrhythmia). The Acizol dose was 60 mg/kg. Survival rate, electrocardiography and histology indices were registered. Experimental studies showed that Acizol can increase an laboratory animal's survival rate by 20%, decrease the heart attack frequency approximately by half, double the a cardiac tonus, and increase the atrioventricular conductivity on 25% in comparison with the control. Acizol has antiarrhythmic properties: lengthening of the latent period by 70% and lengthening the fibrillation time by 80%. The lifespan of the laboratory animals receiving Acizol was increased by 40% in comparison with the control. Acizol is perspective drug for prophylaxis and cardiac ischemia treatment.